Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -58.20 -3.88% 1,443.00 1,439.40 1,441.20 1,490.00 1,420.80 1,485.40 17,998,685 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 15.4 72,396

Glaxosmithkline Share Discussion Threads

Showing 19001 to 19024 of 21075 messages
Chat Pages: Latest  771  770  769  768  767  766  765  764  763  762  761  760  Older
DateSubjectAuthorDiscuss
29/1/2019
08:16
hTTps://www.businessweekly.co.uk/news/academia-research/sanger-and-gsk-scientists-map-route-osteoarthritis-cure
tradermichael
29/1/2019
08:15
Analysts expect GlaxoSmithKline plc (NYSE:GSK) to report $0.70 EPS on February, 6.They anticipate $0.02 EPS change or 2.78 % from last quarter’s $0.72 EPS. GSK’s profit would be $1.70 billion giving it 13.73 P/E if the $0.70 EPS is correct. After having $0.83 EPS previously, GlaxoSmithKline plc’s analysts see -15.66 % EPS growth. The stock increased 0.08% or $0.03 during the last trading session, reaching $38.45. About 1.68M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 8.15% since January 28, 2018 and is uptrending. It has outperformed by 8.15% the S&P500.
tradermichael
29/1/2019
07:23
ECJ and EU are separate bodies.
zicopele
28/1/2019
22:14
I was only 60/40 in favour of remain. Economically I am 100% remain, but I don’t like a lot of aspects about the EU. I think if there was a poll about the reasons for leaving, then leaving the single market would have been well below immigration, ECJ and other things. The express/mail and other media ran 10 consecutive days of anti-immigrant headlines before the vote so you can see what they thought the key issues were. Still I am looking forward to wBecks reasoning on why it’s more important that smaller labs are growing over our bigger pharma’s. The UK biotech sector is littered with corpses of bios that never made it, I invested in enough of them.
dr biotech
28/1/2019
18:23
With a vote 52% Leave 48% Remain it is bound to be very easy to selectively choose folk who say what you wish to hear, which ever side you are on, Dr B! But even on this thread there are views on each side. David Cameron would never have offered the country a choice if he had thought there was any chance of getting a LEAVE result, so like you he must have been persuaded that Remain was a certainty.
jadeticl3
28/1/2019
16:00
Cheap and getting cheaper
zicopele
28/1/2019
13:24
50m a year ongoing cost. Perhaps not “material̶1; but not insignificant. 900 welll paid jobs lost to Amsterdam. There aren’t going to be any winners in the life science industries. Current useless advice is “find alternative markets”. Any decent business is already looking at all the markets they can. Why is it more important that smaller companies grow? They are mostly just contract labs that lack innovation and are incapable of getting drugs through the regulation process. Size is important. The smaller labs that I’ve been in have loads of EU staff that will have to go home or won’t be replaced. To say they are more important is just a puff comment from someone who hasn’t got the slightest clue about the industry.
dr biotech
28/1/2019
11:43
https://seekingalpha.com/article/4235755-glaxosmithkline-watching-dividend-trends-closely
tradermichael
28/1/2019
11:39
I'm tempted to take a few AZN, however noticed their head of oncology left recently. Probably reading too much in to that.
essentialinvestor
28/1/2019
11:24
There is always a major difference between outsourcing a service and being the owner of the IP with its returns. In the middle there are the generics.
alphorn
28/1/2019
11:21
Hardly the end of the world Essential. "Small drug companies grow as big pharma outsources" hTTps://www.telegraph.co.uk/business/2017/01/22/top-50-privately-owned-pharma-companies-britain/ More important imo. Swings and roundabouts. Just as there have been winners(and losers) from 41 years of EU membership, so there will be winners(and losers) when we Leave.
wbecki
28/1/2019
11:08
https://www.theguardian.com/politics/2019/jan/26/european-medicines-agency-closes-london-office-with-loss-of-900-jobs-brexit
essentialinvestor
28/1/2019
11:01
TM - 'material' is an accounting term as you probably know. That would be a very large impact; this ITO does not fall into that category.
alphorn
28/1/2019
10:59
Not according to the board!
tradermichael
28/1/2019
10:41
"not have a material impact" Can still be pretty big!
alphorn
28/1/2019
10:22
Let's have no more of this Project Fear, eh? Our (GSK) approach to Brexit We have evaluated the impact of Brexit on our business operations, including our supply chain and quality oversight. Our priority is to maintain continuity of GSK’s supply of medicines, vaccines and health products to our patients and consumers in the UK and the EU. Uncertainty remains about the future relationship between the UK and the EU. As a result, we have agreed a risk-based approach to mitigation across the organisation. Implementation of our contingency plan has been underway since January 2018, with an immediate focus on our supply chains. This includes expanding our ability in the EU and the UK to conduct re-testing and certification of medicines; transferring Marketing Authorisations registered in the UK to an EU entity; updating packaging and packaging leaflets; amending manufacturing and importation licences, and securing additional warehousing. We currently anticipate that the cost to implement these and other necessary changes could be up to £70 million over the next two to three years, with subsequent ongoing additional costs of approximately £50 million per year, including additional customs duties and transaction or administration costs. These charges represent our estimates of the impact of Brexit based on the information currently available. As more information on the changes to our business that will be required after Brexit becomes available, the assumptions underlying these estimates could change, with consequent adjustments, either up or down, to the additional costs we expect to incur. We will continue to adjust our plans and their expected financial impact as negotiations and regulations develop. Delivering these necessary but complex changes by March 2019 will be ambitious and potentially disruptive in the short term and we support efforts to secure a status quo transition period to minimise disruption. Over the longer term, we continue to believe that Brexit will not have a material impact on our business.
tradermichael
28/1/2019
09:57
Will be interesting to see what they say about brexit. I work a lot in labs and last week I met the first person who admitted they voted out. He’s since changed his mind and would now vote remain. Labs have a lot of well educated Europeans in them - they are going to get clobbered when free movement ends. Plus the EMA relocating to Amsterdam plus customs etc. We’ve relocated our warehouse to Karlsruhe. Only 4 people, but customers need things next day and Europe’s more important.
dr biotech
28/1/2019
09:53
£1 = $1.32, not so good ….. ;0(
tradermichael
28/1/2019
09:12
Results a week on Wednesday (6 February) to bear in mind …… ;0)
tradermichael
28/1/2019
08:50
Usual kiss of death buy rating from HSBC lol Looking to add on any further weakness before ex div 21 Feb
ny boy
27/1/2019
14:30
The new wonder vaccination for Shingles so successful, now a shortage, that's why they fallen.
montyhedge
27/1/2019
13:24
abdulla, strong sterling versus dollar last week makes for weak GSK and is bear point also for VOD.
bolador
27/1/2019
12:42
If we stumble in to a no deal, the hit to GBP makes GSK significantly more attractive on a short term basis. I suppose you could view it as a no deal hedge in that respect. Otherwise my take is lower levels may well be available to add.
essentialinvestor
27/1/2019
12:36
GlaxoSmithKline (LON:GSK) has been given a GBX 1,820 price objective by equities researchers at HSBC in a report released on Friday. The brokerage presently has a “buy” rating on the stock. HSBC’s price target points to a potential upside of 26.35% from the company’s previous close.
tradermichael
Chat Pages: Latest  771  770  769  768  767  766  765  764  763  762  761  760  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200330 01:48:43